and efficacy of rG-CSF-elicited WBC transfusions in patients despite antifungal therapy. We evaluated the role of recombiwith neutropenia-related fungal infections that were refractory nant granulocyte colony-stimulating factor (rG-CSF)-elicited to therapy with amphotericin B. acute branching septated hyphae but the culture evaluation
Pretreatment evaluation included history and physical examination, Zubrod scale performance status and hematologic evaluation, liver and kidney function tests, and appropriIntroduction ate roentgenographic, histopathologic, and culture evaluations of infected sites. Patients were examined and the Neutropenia-related fungal infections can be life-threatening above-mentioned laboratory parameters were monitored daily in cancer patients despite antifungal therapy. 1 The role of during therapy, at the end of therapy, and 3 weeks after the white blood cell (WBC) transfusions in the treatment of neuend of therapy. Patients were also evaluated at least 3 months tropenia-related infections has been examined and remains after the end of therapy. controversial.
2-13
Patients were evaluable for response if they received three The low number of donor cells collected probably accounts or more transfusions. Response was evaluated by two investifor the marginal efficacy of WBC transfusions in some studies.
gators (MCD and EJA). Patients were considered to have a fav-A dose-response was established in some experimental 14 and orable response if they had improvement or stabilization of clinical studies. 8, 11, 15 the clinical and laboratory parameters on the last day of WBC Dexamethasone has been the preferred agent for donor transfusion therapy. stimulation. However, administration of recombinant granuloResponse at 3 weeks and 3 months was defined as precyte colony-stimulating factor (rG-CSF) safely increases the viously reported 1 and was based on a combination of clinical number of circulating neutrophils in patients with neutroand laboratory findings. penia 16 and results in a significantly higher neutrophil yield (1) Complete response: This indicated the disappearance of per collection and a higher absolute neutrophil count (ANC) all clinical and laboratory signs and symptoms of infection in the recipients than the administration of dexamethasone or including radiologic examination, and negative cultures no treatment at all. 17 from previously infected sites when possible. The persistWe conducted this prospective study to evaluate the safety ence of minimal scarring, as determined by a radiologist not participating in the study, was considered as a complete response if no recrudescence of disease was noted ation of therapy or until patient's death, whichever came first, and/or if complete autopsy examination failed to Collection rates varied from 1.5 to 3 ml per min. All WBC concentrates were irradiated with 3000 rad except for four show persistent infection).
(2) Complete response with residuae indicated continuous concentrates collected from a bone marrow donor. In this patient, the intent of the WBC transfusion was to both treat improvement and clinical evolution compatible with the natural history of mold infection and no recrudescence of infection and induce myeloid engraftment (patient 13). disease described above. (a) Pulmonary: defervescence of fever, resolution of clinical signs and symptoms of infection, no new lesions
White-blood cell transfusions or increase in existing lesions, negative respiratory tract cultures, but with persistent pulmonary cavity. The WBC concentrates were infused within 2 h of collection (b) Sinusitis: defervescence of fever, resolution of clinical over 60-90 min and at least 4 h after the amphotericin B signs and symptoms of infections, negative cultures.
infusion. Recipients were premedicated with hydrocortisone The persistence of residual non-specific findings by (100 mg) and diphenhydramine intravenously (25 mg) and sinus X-rays or CT scan did not exclude response if no acetaminophen (650 mg) orally. WBCs were transfused daily recrudescence of disease, as described above, was when possible, and the transfusions were continued until no seen. more donors were available or until patients recovered from (3) Partial response: Partial response indicated clinical myelosuppression (ANC у1000/l for 2 successive days withimprovement, and regression of more than 50% in the size out transfusion), died, had no response to therapy, or were of objective parameters of fungal infection.
cleared of infection. (4) Stable disease: Indicated stabilization in the clinical signs
Complete blood and platelet counts of the concentrates and symptoms of infection, no change in the size of the were obtained with a Coulter automated STKS hematology objective measurements or regression of less than 50% in system (Coulter Corporation, Miami, FL, USA), and a differenthe size of these measurements.
tial count was done manually. (5) Failure: Indicated progressive infection (clinical and/or ANCs were obtained for all patients at baseline and at 1 laboratory).
and 24 h after the WBC transfusions. Occasionally, WBC (6) Relapse: Documented infection with the same organism transfusions were withheld for 24 h because of suspected at any site occurring at any time after discontinuation of bone marrow recovery or because we could not perform leustudy drug. Same organism implies same antibiogram. kapheresis on Sundays. In those cases, the ANC was obtained 48 h after transfusion. A favorable response indicated complete or partial resolution of the infection.
Donor and recipient toxic effects Donors
Toxic effects were assessed daily in all recipients and donors. Recipients were monitored for adverse reactions during the Only related donors were enrolled in the study, except in two 2 h of WBC infusion and for 6 h after the infusion. The severity cases in which spouses were allowed to donate pending the of the reactions was classified as: (1) mild: transient, resolved arrival of related donors. Human lymphocyte antigen (HLA) without medication; (2) moderate: resolved with medication; and blood typing were done on all donors, but no attempt and (3) severe: potentially life-threatening and requiring diswas made to select donors on the basis of antigen or blood continuation of therapy. type compatibility. All donors were screened and accepted according to criteria established by the United States Food and Drug Administration.
Statistical analysis
Donors received 5 g/kg daily of rG-CSF by subcutaneous injection until the day of the last leukapheresis. We chose rGUnivariate logistic regression analyses were performed to CSF instead of recombinant granulocyte-macrophage colonydetermine important predictors of response at the end of therstimulating factor because of the lower incidence of adverse apy. Post-treatment variables thought to have influenced events and the higher level of neutrophilia associated with rGresponse were analyzed using the χ 2 test (to examine differ-CSF therapy. 18 Eighteen to 24 h after their first dose, donors ences in proportions) and the Mann-Whitney test. A P value underwent leukapheresis. Most donors underwent leukapherof Ͻ0.05 was considered significant. Correlation coefficients esis on alternate days, but consecutive donations were among hematologic parameters and between hematologic allowed for male donors when necessary.
parameters and day of leukapheresis were computed.
White blood cell collections
Results WBC concentrates were collected on a continuous-flow blood Patients cell separator (Spectra; Cobe Laboratories, Lakewood, CO, USA) using 500 ml of 10% low molecular weight starch (Pentaspan; Du Pont Critical Care, Waukegan, IL, USA) per Twenty patients were enrolled in the study; 15 were evaluable for response (Table 1) . Five patients received fewer than three procedure, plus 40 ml of 46% citrate concentrate (Haemonetics, Braintree, MA, USA). HES-citrate was infused WBC transfusions because of early death (three patients), bone marrow transplantation (BMT) after the first transfusion (one at 1 ml per liter of donor blood volume per min in a 1:13 anticoagulant/WBC ratio with whole blood. This allowed us patient), and severe pulmonary adverse reaction (one patient). Seventy-three percent of the patients were classified as level to process approximately 7 liters of blood for each procedure. were comparable in both groups (P Ͼ 0.5). White blood cell transfusions 3 or 4 on the Zubrod scale (bedridden for more than 50% of a normal day). Data regarding WBC transfusions and their effect on the 15 evaluable patients are shown in Table 7 . The mean and range Data pertaining to the 15 evaluable patients are shown in Table 2 , which is arranged by infection diagnosis. All patients, of ANCs taken 1, 24 and 48 h after transfusion include patient 10 (the only one who had a baseline ANC Ͼ100/l) but when except for patient 15, had neutropenia refractory to treatment with rG-CSF. Only patient 10 had a baseline ANC Ͼ100/l.
we excluded this patient from the same analysis, our resulting values did not differ significantly; they were a mean of 512/l Detailed information on these 15 patients in regard to WBC transfusion therapy, response of infection, survival, and ulti-(range, 98-1072/l) at 1 h, a mean of 320/l (range, 50-932/l) at 24 h, and a mean of 196/l (range, 0-750/l) at mate outcome of the infection and the malignancy is shown in Table 3 . Table 4 shows the relationship between outcomes 48 h. Figure 1 shows that there was a strong correlation between the donors' ANCs and the yields of neutrophils per of infection and recovery from neutropenia observed in the 15 patients. Favorable outcomes were seen in 11 patients at leukapheresis (r = + 0.9).
Patients with favorable and unfavorable responses at the the end of therapy. Eight of those patients continued to have a favorable outcome 3 weeks later, whereas two patients end of therapy had received a comparable number of total neutrophils per body surface area (mean, 168 × 10 9 and deteriorated (and considered as treatment failures) and one died of infection. The two patients with treatment failure had 202 × 10 9 /transfusion, respectively; P = 0.6) (data not shown). The 1-h post-transfusion ANCs of both groups of recipients suffered relapse of leukemia (patient 10) or persistent of neutropenia and BMT-induced graft-versus-host disease (GVHD)
were also comparable in both groups (mean, 636/l for responders and 480/l for nonresponders; P = 0.6). (patient 13), whereas death was caused partially by the infec- Adverse reactions related to the study treatment two patients with cellulitis (patients 2 and 8). This transient worsening was seen within 24 h of the first WBC transfusion and was followed by subsequent improvement. Four of the WBC transfusions were well tolerated by the recipients; fewer than 5% were associated with adverse reactions. The adverse nine patients with fungal pneumonia had progression of their pulmonary infiltrates during therapy, and two of these patients reactions observed within 6 h of the administration of 130 WBC transfusions to the 20 recipients are shown in Table 8 .
had a favorable outcome. Four of the five remaining patients with fungal pneumonia had a favorable outcome. Only one Moderate reactions improved when patients were treated with steroids (patient 1), diuretics (patient 6), or both (patient 4). patient tested nonreactive for cytomegalovirus (CMV) antibody. Because of the potentially fatal and progressive infecSevere reactions that required discontinuation of therapy were seen after the infusion of 1.5% of the WBC transfusions.
tion and the lack of CMV-negative donors, this patient (patient 2) received WBC transfusions from CMV-positive donors. She Increase of inflammation at the site of infection was seen in seroconverted and received prophylactic gancyclovir. She did trophils transfused (three-fold to four-fold higher than conventional WBC transfusions). Experimental and clinical not develop CMV disease.
Four of 35 donors complained of mild myalgias and arthralstudies have shown that the number of transfused cells is a major determinant of the efficacy of WBC transfusion gias that resolved with the administration of acetaminophen alone. The values of serum lactic dehydrogenase (LDH), alkatherapy. 8, 11, 14, 15 Although the mean yield of neutrophils per rG-CSF-elicited line phosphatase (AP), and serum alanine transferase (ALT) increased per day of collection for all donors. After the fifth WBC transfusion was about 50% lower than that obtained in another study by using donors with chronic myelocytic leukeday of donation, the mean values of LDH, AP, and ALT were 1.8, 2.6, and 3.2 times higher than baseline, respectively (data mia donors, 15 the post-transfusion ANCs in our recipients were not so different. In both studies, transfused neutrophils not shown).
could be seen in the circulation for as long as 2 days after transfusions. This apparent prolongation of neutrophil survival might be explained by the following factors: (1) leukocytes Discussion harvested from rG-CSF-treated donors include neutrophil precursors 17 whose proliferation could be enhanced by the rGThis is the first prospective study of rG-CSF-elicited and irradiated WBC transfusions in the treatment of neutropenia-CSF treatment given to both the donors and the recipients 18 and (2) donor and recipient rG-CSF treatments could have related fungal infections. Our findings indicate that the procedure was well tolerated by both donors and patients and prolonged the survival of transfused WBCs by decreasing apoptosis. 19 We did not systemically assess the degree of that these transfusions may be effective in severely ill patients with refractory and neutropenia-related fungal infections. The maturity and the functional activity of the collected cells, although, from previous experience at our institution, we did beneficial effect of these transfusions seemed to be enhanced by their administration to patients with good performance find CD34 + cells in some of the WBC concentrates obtained from subjects not included in this study (unpublished data). status and early during the period of neutropenia and soon after the onset of the fungal infection. An earlier study with
The status of alloimmunization of the recipients has been shown to have an effect on the outcome of infection and on conventional WBC transfusions also suggested that the early administration of WBC transfusions may be an important prethe adverse reactions related to this therapy. 20 While we did not assess the alloimmunization status of our patients, all were dictor of outcome.
3 Transfused neutrophils remained in circulation in levels greater than 500/l and 200/l for 24 and 48 h at risk of being alloimmunized because of prior transfusions. The fact that most of our donors were related and shared more after their infusions, respectively.
The beneficial effect of WBC transfusion therapy in this than two HLA antigens could have also contributed to the high response rate obtained in our study. study could be partially explained by the high number of neu- The four responders in our study who recovered from their rapidly progressive and severe infections at study entry.
Failures of WBC transfusion therapy were probably caused by the advanced stage of the infection at study entry. The four patients who did not benefit from the WBC transfusions had toms related to the rG-CSF treatment. The incidence was about half that reported in patients treated with rG-CSF after the worst performance status (three of them were on ventilators at study entry) and had been profoundly neutropenic chemotherapy. 16 The rises in alkaline phosphatase and lactate dehydrogenase levels among the donors were expected and with active fungal infection for much longer than the patients who did benefit from WBC transfusions.
comparable with the levels observed in patients on day 6 of treatment with rG-CSF, 21 and may have been related to an Six patients had an initially favorable response to the WBC transfusion therapy but failed at 21 days and/or 3 months after increased turnover in WBCs. Uric acid serum levels were not measured, but no donor had any clinical manifestation the last WBC transfusion. In five of these patients, the progression or reactivation of their infections occurred after the attributable to hyperuricemia. The rise in alanine aminotransferase has not previously been reported as a side-effect discontinuation of the transfusions and was related to greater impairment of their immune system. It is possible that some related to treatment with either rG-CSF or HES. There are several limitations to our study, including the of these patients could have responded favorably, had they received WBC transfusions during the period of subsequent small sample size and the lack of controls. A selection bias, particularly one based on the availability of related donors, neutropenia.
Eleven percent of the donors had musculoskeletal sympcould have also occurred. persistent neutropenia could benefit from rG-CSF-elicited and irradiated WBC transfusions; however, transfusion therapy is a temporary measure to be used only in patients who are likely to recover from neutropenia and to achieve remission of their underlying malignancies. In such patients, transfusions should be started soon after the onset of the infection. This new promising and safe modality of therapy deserves further investigation in larger controlled clinical trials. In conclusion, patients with refractory fungal infections and
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